101 related articles for article (PubMed ID: 16637233)
21. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice.
Dluzen DE; Kefalas G
Brain Res; 1996 Nov; 741(1-2):215-9. PubMed ID: 9001725
[TBL] [Abstract][Full Text] [Related]
22. Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease.
Anandhan A; Tamilselvam K; Radhiga T; Rao S; Essa MM; Manivasagam T
Brain Res; 2012 Jan; 1433():104-13. PubMed ID: 22138428
[TBL] [Abstract][Full Text] [Related]
23. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
24. Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease.
Pain S; Gochard A; Bodard S; Gulhan Z; Prunier-Aesch C; Chalon S
Exp Toxicol Pathol; 2013 Jul; 65(5):689-94. PubMed ID: 23083629
[TBL] [Abstract][Full Text] [Related]
25. Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase.
Zhang W; Wang T; Qin L; Gao HM; Wilson B; Ali SF; Zhang W; Hong JS; Liu B
FASEB J; 2004 Mar; 18(3):589-91. PubMed ID: 14734632
[TBL] [Abstract][Full Text] [Related]
26. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
Sconce MD; Churchill MJ; Greene RE; Meshul CK
Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
[TBL] [Abstract][Full Text] [Related]
27. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
28. Isotopic reinforcement of essential polyunsaturated fatty acids diminishes nigrostriatal degeneration in a mouse model of Parkinson's disease.
Shchepinov MS; Chou VP; Pollock E; Langston JW; Cantor CR; Molinari RJ; Manning-Boğ AB
Toxicol Lett; 2011 Nov; 207(2):97-103. PubMed ID: 21906664
[TBL] [Abstract][Full Text] [Related]
29. Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Matheus FC; Aguiar AS; Castro AA; Villarinho JG; Ferreira J; Figueiredo CP; Walz R; Santos AR; Tasca CI; Prediger RD
Behav Brain Res; 2012 Dec; 235(2):263-72. PubMed ID: 22921927
[TBL] [Abstract][Full Text] [Related]
30. Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin.
Parain K; Hapdey C; Rousselet E; Marchand V; Dumery B; Hirsch EC
Brain Res; 2003 Sep; 984(1-2):224-32. PubMed ID: 12932857
[TBL] [Abstract][Full Text] [Related]
31. Recovery of motor function and dopaminergic parameters in a mouse model of Parkinson's disease induced by co-administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate.
Shimazu S; Takahata K; Tamashiro A; Yoneda F; Iida Y; Saji H
J Neural Transm (Vienna); 2003 Aug; 110(8):871-83. PubMed ID: 12898343
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective effects of (Val8)GLP-1-Glu-PAL in the MPTP Parkinson's disease mouse model.
Zhang Y; Chen Y; Li L; Hölscher C
Behav Brain Res; 2015 Oct; 293():107-13. PubMed ID: 26187689
[TBL] [Abstract][Full Text] [Related]
33. Vertical grid test and modified horizontal grid test are sensitive methods for evaluating motor dysfunctions in the MPTP mouse model of Parkinson's disease.
Kim ST; Son HJ; Choi JH; Ji IJ; Hwang O
Brain Res; 2010 Jan; 1306():176-83. PubMed ID: 19804765
[TBL] [Abstract][Full Text] [Related]
34. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
[TBL] [Abstract][Full Text] [Related]
35. [Effect of the oil from ganoderma lucidum spores on pathological changes in the substantia nigra and behaviors of MPTP-treated mice].
Zhu WW; Liu ZL; Xu HW; Chu WZ; Ye QY; Xie AM; Chen L; Li JR
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):667-71. PubMed ID: 15958304
[TBL] [Abstract][Full Text] [Related]
36. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
Pifl C; Schingnitz G; Hornykiewicz O
Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
[TBL] [Abstract][Full Text] [Related]
37. Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.
Liang Y; Li S; Zou Q; Su B
Neurosci Lett; 2006 Jun; 400(3):213-7. PubMed ID: 16540245
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
Liu W; Jalewa J; Sharma M; Li G; Li L; Hölscher C
Neuroscience; 2015 Sep; 303():42-50. PubMed ID: 26141845
[TBL] [Abstract][Full Text] [Related]
39. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
[TBL] [Abstract][Full Text] [Related]
40. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
